Radioconjugates targeting cd33 in the treatment of breast cancer
US-2026053963-A1 · Feb 26, 2026 · US
This page is not indexed by search engines while we improve data quality.
Berger Mark patents
Berger Mark is listed as an inventor on 15 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Berger Mark |
| Total patents | 15 |
| First publication | Aug 13, 2020 |
| Latest publication | Feb 26, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Radioconjugates targeting CD33 in the treatment of cancers
US-12539340-B2 · Feb 3, 2026 · US
Radioconjugates targeting CD33 in the treatment of sarcomas
US-12491274-B2 · Dec 9, 2025 · US
Methods for treatment of patients with myelodysplastic syndromes
US-2024408250-A1 · Dec 12, 2024 · US
Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225
US-2024299600-A1 · Sep 12, 2024 · US
Methods for treatment of patients with myelodysplastic syndromes
US-12083192-B2 · Sep 10, 2024 · US
Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-2024158528-A1 · May 16, 2024 · US
Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-11912780-B2 · Feb 27, 2024 · US
Radioconjugates targeting cd33 in the treatment of cancers
US-2023302167-A1 · Sep 28, 2023 · US
Radioconjugates targeting cd33 in the treatment of cancers
US-2023092668-A1 · Mar 23, 2023 · US
Recent patents
Latest publications not already listed above.
Anti-cd45-based lymphodepletion methods and uses thereof in conjction with act-based cancer therapies
US-2021198359-A1 · Jul 1, 2021 · US
Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy
US-2021179710-A1 · Jun 17, 2021 · US
Methods for cancer treatment using a radiolabeled anti-cd45 immunoglobulin and adoptive cell therapies
US-2020308280-A1 · Oct 1, 2020 · US
Methods for treatment of patients with myelodysplastic syndromes
US-2020276339-A1 · Sep 3, 2020 · US
Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-2020255520-A1 · Aug 13, 2020 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Actinium Pharmaceuticals Inc | 15 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K51/1027 | 15 |
| A61P35/00 | 12 |
| A61K2039/505 | 11 |
| C07K16/2803 | 10 |
| A61K51/1096 | 10 |